Crinetics Pharmaceuticals reported Q1 2026 on May 7 ↗ with Palsonify (paltusotine) at $10.3 million in net product revenue, the first full commercial quarter for the once-daily oral somatostatin receptor 2 agonist approved last year for acromegaly. The print nearly doubled the $5.4 million Q4 2025 launch quarter, brought 263 unique prescribers (up from 125 at year-end), 232 new patient enrollment forms, and reimbursement at roughly 70% of patients with payer coverage above 60%. Cash, equivalents, and investments closed at $1.3 billion. Shares rose 4.3% in after-hours trading.
Why this matters. Acromegaly is a rare disease (roughly 25,000 US patients). The standard of care for decades has been monthly injectable somatostatin analogs (octreotide, lanreotide), which work but require either monthly clinic visits for injection or self-administration with substantial discomfort. Palsonify is the first oral, once-daily SSTR2 agonist for the indication. The launch trajectory matters because rare-disease specialty drugs typically take 4 to 6 quarters to reach steady-state penetration, and the doubling between Q4 and Q1 plus the prescriber-base doubling suggests Palsonify is on the higher-end of that ramp curve.
The peptide-design angle. Palsonify (paltusotine) is a small molecule, but the SSTR2 receptor it engages is the same target the field's classic peptide somatostatin analogs (octreotide, lanreotide, pasireotide) have hit for forty years. Crinetics' design accomplishment was finding an orally bioavailable small-molecule agonist of a peptide receptor where prior work had been entirely peptide-based. The platform's SSTR2-related coverage ↗ (the April 26 piece on a small-molecule SSTR2 conjugate challenging Lutathera in neuroendocrine tumors) reflects the same broader pattern: peptide-receptor pharmacology now includes both peptide and small-molecule ligand classes, and the commercial competition between them is starting to mature.
The pipeline behind Palsonify. R&D rose 17.6% to $100.1 million in the quarter to fund Phase 3 paltusotine in carcinoid syndrome (the diarrhea-and-flushing presentation of metastatic neuroendocrine tumors that produce excess serotonin), plus atumelnant Phase 3 programs in congenital adrenal hyperplasia and Cushing's syndrome. The company's strategy is sequential rare-endocrine-disease drugs leveraging the same SSTR2-or-related receptor pharmacology and the same commercial infrastructure (rare-disease sales force, specialty pharmacy distribution, prior-authorization expertise). Each new approved drug reuses the patient-finding and reimbursement machinery the previous launch built.
The broader rare-disease commercial context. The acromegaly market is small in patient terms but has high per-patient revenue ($150K-$300K annual treatment cost) because of the complexity of the disease and the lack of alternatives. Palsonify's $10.3M Q1 puts the run-rate at roughly $40M annualized at this trajectory, which understates expected steady-state because the prescriber base is still growing. The 263 prescriber count includes endocrinologists who specialize in pituitary disease and pediatric endocrinologists who treat acromegaly's growth-related variants. Reaching the 75% reimbursement target by Q3 (the company's stated goal) would clear the largest commercial friction point.
The platform read. The platform's SSTR2 target page ↗ anchors the section's coverage of somatostatin-receptor pharmacology. Palsonify is small-molecule, not a peptide card, but the SSTR2 receptor target has been broadly important in the platform's neuroendocrine-tumor and acromegaly coverage. As Crinetics expands paltusotine into carcinoid syndrome (a neuroendocrine indication that has historically been peptide-treated with Lutathera and similar agents), the small-molecule-vs-peptide commercial competition becomes a more central question for the platform's design space.
What 2026 has to clarify. Whether Palsonify continues doubling quarter-over-quarter or settles into a slower growth pattern as the most-easily-reached patient population gets covered. Whether the carcinoid syndrome Phase 3 program (the same paltusotine molecule, different indication) reads positively in 2027. And whether the atumelnant adrenal programs deliver complementary revenue trajectories that establish Crinetics as a multi-product rare-endocrine-disease franchise rather than a single-drug company.